



AGENDA

Meeting of the SWAG Network Urological Cancer Clinical Advisory Group
Thursday 29th January 2026, 13:00-17:00
Cotswold Suite, Aztec Hotel, Aztec West, Almondsbury, Bristol, BS32 4TS

Chair: Jonathan Aning

<u>13:00-13:30</u>	LUNCH	<u>Join the meeting now</u>
<u>13:30-13:40</u>	Introductions, last meeting's report and actions	Jon Aning
<u>13:40-13:50</u>	Task and Finish Group update: PSMA PET and targeted biopsy	Jon Aning
	Clinical guidelines	
<u>13:50-14:10</u>	SWAG Clinical Guidelines: Consensus view on optimal use of the PSA blood test in Primary Care	Anthony Kouparis
<u>14:10-14:30</u>	National Cancer Programme Planning Priorities for 2026	Nicola Gowen
	Quality indicators, audits and data collection	
<u>14:30-14:40</u>	SWAG Outputs from 'Days Matter' Cancer Challenge	Ruth Carr & Nicola Gowen
<u>14:40-15:30</u>	The role of MRI in the suspected bladder cancer pathway – results from a multicentre SWAG audit	Tom Malik
	Haematuria pathways – an update on ARMADA-BCP	Jon Aning
<u>15:30-15:40</u>	Refreshment Break	
	Coordination of patient care pathways	
<u>15:40-15:50</u>	Is there a need in SWAG to improve the quality of Primary Care referrals?	Leah Pearson
<u>15:50-16:10</u>	South West Prostate Cancer Dashboard – automated data entry and plans for 2026	Nick Burns-Cox
	Patient experience	
<u>16:10-16:20</u>	SWAG-wide CNS Education Event 14 th October 2025	Michelle Syms
	Research	
<u>16:20-16:35</u>	Research Delivery Network update	Claire Matthews/Amit Bahl
<u>16:35-16:40</u>	Cancer Vaccine Launch Pad	Tony Timlin
	Service development	
<u>16:40-16:55</u>	GMSA prostate genomic pathway	Siobhan John
<u>16:55-17:00</u>	Any other business/date and agenda of next meeting	All



astellas



MERCK nonACUS

Astellas, AstraZeneca, Merck and Nonacus have provided sponsorship towards this independent Programme. Astellas, AstraZeneca, Merck and Nonacus have had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.